Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Wednesday. The firm issued a hold rating on the stock.

A number of other analysts have also recently weighed in on EKSO. HC Wainwright decreased their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital decreased their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Trading Up 4.7 %

NASDAQ:EKSO opened at $0.70 on Wednesday. The stock’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.07. The company has a market capitalization of $15.29 million, a PE ratio of -1.02 and a beta of 1.47. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. Ekso Bionics has a 52-week low of $0.66 and a 52-week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter in the prior year, the business earned ($0.24) EPS. On average, research analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.